about
Viral hepatitis infections in chronic kidney disease patients and renal transplant recipientsSafety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Expression of Biliverdin Reductase A in peripheral blood leukocytes is associated with treatment response in HCV-infected patientsFinal Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.Historical epidemiology of hepatitis C virus (HCV) in selected countries.Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.Toxic Epidermal Necrolysis After Exposure to Dithiocarbamate Fungicide Mancozeb.Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.Predictive role BLVRA mRNA expression in hepatocellular cancer.Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.Strategies to manage hepatitis C virus (HCV) disease burden.Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms.Chelating polymeric beads as potential therapeutics for Wilson's disease.Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C.Propofol-induced acute pancreatitis.Long-term follow-up of Wilson Disease: natural history, treatment, mutations analysis and phenotypic correlation559 CNS impairment in the children from patients with Wilson diseaseAnemia as a predictor of response to antiviral therapy in chronic hepatitis CT helper, cytotoxic T lymphocyte, NK cell and NK-T cell subpopulations in patients with chronic hepatitis CEffect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changesFunctional variants of eNOS and iNOS genes have no relationship to the portal hypertension in patients with liver cirrhosisEpidemiology of HCV infection in the Central European regionNew therapeutic options for HCV in Central Europe
P50
Q27023104-D7A1DF4A-66AA-432A-8665-FEE9D86BF381Q33834742-5EA36EE9-5F65-44E8-BCA2-90E24D3A022EQ34638990-66933077-50BA-4280-93A8-5BE96418329DQ35785198-D52A21FD-5B0E-46DD-A49F-BF90989D7343Q36724400-08E151B7-B66C-4E02-9989-4AC782FE6515Q38203033-29AEE0E8-457B-4C2D-A0CF-066036B7B283Q38388633-C06CCEBD-DAA8-47F2-B71B-6EF974412E9DQ39213684-C1C1BAA5-1D88-4F32-80D6-AE176EC23CCCQ40151645-58D83F71-920A-4BAA-A605-654426BFC176Q40169424-3A2F0795-39E2-430A-9EE9-3182609D1542Q40542353-A5B7D6F5-10F6-4973-857B-C53A6A9F0DF1Q42209774-EDC860C7-B889-4977-849A-3650FE6F3AC4Q42226125-23632DA3-BD49-4265-818F-393B5A88568EQ43040357-9BE4C5DE-0AAF-4368-BF1A-621BD8133B9CQ45341390-0A5ECEDF-E5C9-48A6-9A98-D7D3CD6C803AQ48782562-30B63985-7E83-4958-A45A-0A34F814B0FAQ50583336-0D0B64AE-566F-42F7-A5C3-96CCE8C5E80AQ54380725-62980B20-545D-4ECB-88BA-FF928F4AD31FQ60034714-C630B347-85E2-42C6-87F1-3A66B1BC55E9Q60034736-20F58FAC-78C9-4C78-8A16-D8070A2BF277Q62977380-AE5F1029-3CB2-4F0F-B5F9-AA3E708A3149Q73109565-2DE7CD40-FE36-4761-B987-B158F3B62D97Q79354256-88AD33E4-B6C3-4D59-831E-6E9F67CBE50EQ86241401-8BBF5544-0BA6-4D60-BC5E-A89D5E3518AEQ88881090-DCCDD829-CC76-4D04-94F7-308DF5779133Q88881094-5208C9DE-58AB-4569-B171-619D0DFE5908
P50
description
researcher, ORCID id # 0000-0002-1506-1135
@en
wetenschapper
@nl
name
Petr Urbanek
@ast
Petr Urbanek
@en
Petr Urbanek
@es
Petr Urbanek
@nl
type
label
Petr Urbanek
@ast
Petr Urbanek
@en
Petr Urbanek
@es
Petr Urbanek
@nl
prefLabel
Petr Urbanek
@ast
Petr Urbanek
@en
Petr Urbanek
@es
Petr Urbanek
@nl
P106
P31
P496
0000-0002-1506-1135